The first aim of this grant was to compare the motility results provided by the GutTracker Wireless Patch System with an existing FDA cleared measurement, the Medtronic SmartPill. GutTracker results are reported in terms of the frequencies and strengths of peaks in time-based frequency spectra. These were shown to be in concordance with spectral analysis of simultaneous SmartPill pressure measurements. Some of this data was used in a successful FDA 510k submission to validate this unique new measurement modality and assign the frequencies to either the stomach, small intestine and colon. The second aim involved tests with volunteers where stimulant drugs were administered while they were being monitored. Some, but not all, colonic stimulants were found to produce strong peaks in the spectral region believed to be colonic based on the SmartPill testing. The result led to an understanding that the system can objectively examine the effect of drugs.